Document is current

Article History

Received: 22 January 2025

Revised: 9 April 2025

Accepted: 5 May 2025

First Online: 21 May 2025

Declarations

:

: The Institutional Review Board and the Ethics Committee of the Ludwig-Maximilians-University, Munich, approved the surgical removal as well as the histopathologic preparation and analysis of the patients’ specimens (No. 22–1034). The study was conducted according to the tenets of the Declaration of Helsinki.

: Informed consent was obtained from all individual participants included in the study.

: Denise Vogt: travel reimbursements and speaker fees by AbbVie Germany GmbH & Co. KG, Novartis Pharma GmbH and Bayer Vital GmbH.Viktoria Deiters: travel reimbursement by AbbVie, speaker fee by Novartis.Yulia Zaytseva: None to declare.Ricarda G. Schumann: research grant, travel reimbursement, personal fee and non-financial support by Novartis, Bayer, AbbVie, Roche and Zeiss.Armin Wolf: Consultant with AbbVie, Bayer, Boehringer Ingelheim, Novartis, Pixium, Roche, Sandoz, and Zeiss.Siegfried G. Priglinger: Novartis Pharma GmbH advisory board/honoraria, Pharm Allergan advisory board/honoraria, Zeiss advisory board/honoraria, BVIadvisory board/honoraria.Julian E. Klaas: Consultant for ROCHE. Speaker Honoraria for Roche, Novartis.All authors attest that they meet the current ICMJE criteria for authorship.The authors have no proprietary interest in any aspect of this study.

: This study uses surgically removed human tissue from human participants.